Gland Pharma gets tentative US FDA nod for brimonidine tartrate eye solution
This story was originally published at 11:39 IST on 4 March 2026
Register to read our real-time news.Informist, Wednesday, Mar. 4, 2026
MUMBAI – Gland Pharma Ltd. has received tentative approval from the US Food and Drug Administration for its abbreviated new drug application for brimonidine tartrate ophthalmic solution with 0.025% concentration. The ophthalmic solution is used to treat redness in the eye.
The ophthalmic solution had sales of approximately $39 million in the US for the 12 months ended September, Gland Pharma said, quoting data from IQVIA.
For the December quarter, Gland Pharma had, on a consolidated basis, reported a net profit of INR 2.61 billion on a revenue of INR 16.95 billion. At 1120 IST, its shares were down 2.8% at INR 1,744 on the National Stock Exchange. End
US$1 = INR 92.27
IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT
Reported by Ruchira Kagita
Edited by Rajeev Pai
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
